HomeBioPharma

BioPharma

BioPharma

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

-

BioPharma

Biogen buys rights to Stoke’s rare epilepsy drug

BioPharma

FTC sues major pharmacy benefit managers over insulin prices

BioPharma

AstraZeneca, Daiichi’s Enhertu successor faces more questions after latest stumble

BioPharma

Biogen, UCB get the lupus data they’ve waited two decades for

BioPharma

Leveraging NGS to move precision oncology forward, from CDx to commercialization

0

BioPharma

Biotech startups are built on venture capital. Track funding rounds here.

0

BioPharma

How Intra-Cellular surprised Wall Street by breaking character

0

BioPharma

Are You Using Next-Gen Sequencing to inform AAV product and process quality? Here are 4 reasons you should

0

BioPharma

Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise

0

BioPharma

Gene therapy uptake in sickle cell stays slow, despite patient interest

0

BioPharma

Editas to lay off staff after search for sickle cell partner comes up empty

0

BioPharma

CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug

0

BioPharma

FDA panel seeks more data on RSV vaccine safety in infants

0

BioPharma

Merck moves into obesity with deal for Hansoh’s GLP-1 pill

0

BioPharma

Tessera gets sickle cell funding; Corvus shares slide on eczema data

0

BioPharma

Roche sticks with Parkinson’s drug despite second study failure

0

123 4 Page 2 of 4

Most Read

Solid says early data suggest ‘differentiated’ Duchenne gene therapy

Biogen buys rights to Stoke’s rare epilepsy drug

FTC sues major pharmacy benefit managers over insulin prices

Top 10 Companies in Biosimilars Production